Several pharmacological agents that artificially reduce PICs in animal spinal neurons are available for human use. Riluzole, a specific, progressive NaP current inhibitor (Ptak et al. 2005; Urbani and Belluzzi 2000) has been proposed as a promising neuroprotective treatment for acute SCI (Baptiste and Fehlings 2006; Fehlings and Baptiste 2005; Hawryluk et al. 2008; Schwartz and Fehlings 2002). CaP current blockers, such as nimodipine, (Harvey et al. 2006; Li and Bennett 2003), have also been tested as a potential treatment in acute SCI to reduce neuronal excitability (Fehlings and Baptiste 2005; Pointillart et al. 2000; Winkler et al. 2003). Isradipine, a channel-specific CaP current blocker (Fitton and Benfield 1990), has been proposed as a preventative and acute treatment for Parkinson's disease (Surmeier 2007).